Technical Analysis for NEXI - NexImmune, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Death Cross | Bearish | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 4.60% | |
| Stochastic Reached Oversold | Weakness | 4.60% | |
| Wide Bands | Range Expansion | 4.60% | |
| Oversold Stochastic | Weakness | 4.60% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.58% | |
| NR7 | Range Contraction | -0.58% | |
| Narrow Range Bar | Range Contraction | -0.58% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 23 hours ago |
| Outside Day | about 23 hours ago |
| Fell Below Previous Day's Low | about 23 hours ago |
| 10 DMA Resistance | about 24 hours ago |
| Rose Above Previous Day's High | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.6949 |
| 52 Week Low | 1.2501 |
| Average Volume | 73,837 |
| 200-Day Moving Average | 5.53 |
| 50-Day Moving Average | 5.52 |
| 20-Day Moving Average | 4.00 |
| 10-Day Moving Average | 3.43 |
| Average True Range | 0.50 |
| RSI (14) | 35.90 |
| ADX | 24.38 |
| +DI | 18.33 |
| -DI | 24.46 |
| Chandelier Exit (Long, 3 ATRs) | 4.31 |
| Chandelier Exit (Short, 3 ATRs) | 4.50 |
| Upper Bollinger Bands | 5.56 |
| Lower Bollinger Band | 2.44 |
| Percent B (%b) | 0.31 |
| BandWidth | 77.94 |
| MACD Line | -0.67 |
| MACD Signal Line | -0.72 |
| MACD Histogram | 0.0524 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.90 | ||||
| Resistance 3 (R3) | 3.91 | 3.75 | 3.82 | ||
| Resistance 2 (R2) | 3.75 | 3.62 | 3.74 | 3.79 | |
| Resistance 1 (R1) | 3.58 | 3.54 | 3.66 | 3.57 | 3.76 |
| Pivot Point | 3.42 | 3.42 | 3.46 | 3.42 | 3.42 |
| Support 1 (S1) | 3.25 | 3.29 | 3.33 | 3.25 | 3.06 |
| Support 2 (S2) | 3.09 | 3.22 | 3.09 | 3.03 | |
| Support 3 (S3) | 2.92 | 3.09 | 3.00 | ||
| Support 4 (S4) | 2.92 |
